复星医药(600196.SH)发布上半年业绩，归母净利润17.02亿元，同比增长38.96%

Core Insights - Fosun Pharma (600196.SH) reported a revenue of 19.514 billion yuan for the first half of 2025, representing a year-on-year decrease of 4.63% [1] - The net profit attributable to shareholders increased by 38.96% to 1.702 billion yuan [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 23.39% to 0.961 billion yuan [1] - Basic earnings per share stood at 0.64 yuan [1] Revenue Analysis - The decline in revenue is primarily attributed to the impact of centralized drug procurement and the continuation of procurement policies in certain regions [1] - Despite the overall revenue decrease, the income from innovative drugs showed steady growth during the reporting period [1]